Citrobacter amalonaticus strain:99_S182 Genome sequencing and assembly

The bacterial strain Citrobacter amalonaticus was isolated from a surgical site infection in a human patient. Identification was performed using Vitek 2 and Vitek MS (MALDI-TOF). Antimicrobial susceptibility testing via Vitek 2 showed resistance to Augmentin, Cefazolin, Cefuroxime, Ceftriaxone, Ceftazidime, Cefepime, Piperacillin-tazobactam, Meropenem, and Imipenem. The isolate was intermediate to Gentamicin and sensitive to Amikacin, Trimethoprim-sulfamethoxazole, Nitrofurantoin, and Fosfomycin. E-tests confirmed resistance to Ceftazidime-Avibactam (MIC >=256 mg/L), Meropenem (MIC >=32 mg/L), and Imipenem (MIC >=32 mg/L), while Colistin was effective (MIC 0.94 mg/L). The isolate was also resistant to Aztreonam. Molecular testing using GeneXpert detected carbapenemase genes NDM, KPC, and OXA-48.